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Summary
 
It has been proposed that CD2, which is highly expressed on T cells, serves to enhance T cell–
antigen presenting cell (APC) adhesion and costimulate T cell activation. Here we analyzed the
role of CD2 using CD2-deficient mice crossed with transgenic mice expressing a T cell recep-
tor specific for lymphocytic choriomeningitis virus (LCMV)-derived peptide p33. We found
that absence of CD2 on T cells shifted the p33-specific dose–response curve in vitro by a factor
of 3–10. In comparison, stimulation of T cells in the absence of lymphocyte function–associ-
ated antigen (LFA)-1–intercellular adhesion molecule (ICAM)-1 interaction shifted the dose–
response curve by a factor of 10, whereas absence of both CD2–CD48 and LFA-1–ICAM-1
interactions shifted the response by a factor of 
 
z
 
100. This indicates that CD2 and LFA-1 facil-
itate T cell activation additively. T cell activation at low antigen density was blocked at its very
 
first steps, as T cell APC conjugate formation, TCR triggering, and Ca
 
2
 
1
 
 fluxes were affected by
the absence of CD2. In vivo, LCMV-specific, CD2-deficient T cells proliferated normally
upon infection with live virus but responded in a reduced fashion upon cross-priming. Thus,
CD2 sets quantitative thresholds and fine-tunes T cell activation both in vitro and in vivo.
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T
 
cell activation is a carefully orchestrated process that
involves the TCR and a multitude of accessory mole-
cules expressed on T cells and APCs. Operationally, two
types of molecules that modulate TCR-mediated T cell ac-
tivation can be distinguished: (a) accessory molecules such
as LFA-1, which facilitate TCR triggering by promoting T
cell–APC adhesion (1, 2); and (b) costimulatory molecules
such as CD28, which enhance T cell activation without af-
fecting the rate of TCR triggering (2, 3).
Until recently, it was not possible to easily distinguish
between accessory and costimulatory molecules, as there
was no means to experimentally separate TCR triggering
from the outcome of T cell activation. However, the ob-
servation that functionally engaged TCRs are rapidly inter-
nalized (4) now allows us to quantitatively assess TCR trig-
gering and dissect it from T cell activation. It has previously
been shown that TCR internalization occurs normally in
the absence of CD28 (2). Although it is possible that some
molecules may affect the ratio of TCR engagement/inter-
nalization, TCR downregulation is, at this time, the best
assay to measure TCR triggering with minimal influence
by costimulatory molecules. We have previously taken ad-
vantage of this possibility and used it to analyze the respec-
tive roles of LFA-1 and CD28 in T cell activation (2). In this
study, we assessed the role of CD2 in a similar experimen-
tal setup.
CD2, a member of the Ig superfamily, is highly ex-
pressed on T cells and can bind to CD58/LFA-3 (5), CD59
(6), or CD48 (7, 8) expressed on APCs. In mice, CD48 ap-
pears to be the major, if not the only, ligand. The interac-
tion of CD2 with its ligand(s) has been extensively studied
at both the physicochemical and the structural level. The
affinity of CD2 for CD58 or CD48 was found to be low
(
 
z
 
5 
 
3
 
 10
 
2
 
5 
 
M for mouse CD48 and somewhat higher for
human CD58) and to exhibit rapid on and off rates (for re-
view see reference 9). However, the fact that both CD2
and its ligands are membrane bound is critical for their in-
teraction, as it restricts the localization of receptors and ligands
essentially to two dimensions. This increases the operational
concentrations of the compounds and has been referred to
as two-dimensional affinity (10, 11). Similar rules apply to
other membrane-bound receptor ligand pairs, as has been
pointed out for the TCR MHC–peptide interaction (12, 13).
Various roles for CD2 in T cell activation have been
proposed, including function as an adhesion molecule (1,
14–16), thereby reducing amounts of antigen required for
T cell activation (14), as a costimulatory molecule (17–19),
or as a direct promoter of T cell activation (20). Moreover,
CD2 has been implicated in the induction of T cell anergy
(21, 22) and has been reported to modulate cytokine pro-
duction by T cells (23, 24) and regulate positive selection
(25). Surprisingly, however, CD2-deficient mice did not
show an obvious phenotype and could efficiently cope
with viral infections (26, 27), undermining the view that
CD2 plays a major role in T cell activation. Only recently,
CD2 again attracted attention, because CD2AP, a CD2 
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adapter protein, has been shown to help orchestrate recep-
tor patterning and cytoskeletal rearrangement (28).
To quantitatively analyze the role of CD2 in T cell acti-
vation both in vitro and in vivo, we crossed transgenic
mice expressing an MHC class I–restricted TCR specific
for lymphocytic (L)CMV-derived peptide p33 (29), with
CD2-deficient mice (26) and analyzed the functional prop-
erties of the CD2-deficient T cells. We found that CD2 re-
duces the minimal amount of antigen required for T cell
activation both in vitro and in vivo, a function shared with
LFA-1 (2). The results show that CD2 does not promote T
cell activation by a costimulatory mechanism as described
for CD28 (2, 3, 30) but, rather, by simply facilitating T
cell–APC interaction at low antigen concentrations. Such a
mechanism is compatible with a critical role for CD2 in or-
ganizing the T cell–APC contact site.
 
Materials and Methods
 
Mice and Viruses.
 
Transgenic mice expressing a TCR specific
for peptide p33 in association with H-2D
 
b 
 
(29) and CD2- (26)
and intercellular adhesion molecule (ICAM)
 
1
 
-1–deficient (31) mice
have been described previously. LCMV-WE was grown on L cells
at a low multiplicity of infection. Recombinant vaccinia virus ex-
pressing LCMV-GP (Vacc-LCMV-GP) (32) was originally ob-
tained from Dr. D.H.L. Bishop (Oxford University, Oxford, UK)
and was grown on BSC cells at a low multiplicity of infection.
Vacc-LCMV-GP was inactivated with UV light using an XL-1500
UV cross-linker (Spectronics Corp.). To produce recombinant
LCMV-GP for the cross-priming experiments, Vacc-LCMV-GP
was inactivated by UV light and used to infect BSC cells at a
multiplicity of infection of 10. 24 h later, cells were harvested and
sonicated. Cell debris corresponding to 5 
 
3
 
 10
 
6
 
 cells was injected
per recipient.
 
Peptides.
 
Peptides p33 (KAVYNFATM) and A4Y (KAVAN-
FATM) were generated at the Amgen Institute (Boulder, CO) by
a solid phase method using the Fmoc/tBu-based protocol on an
ABI-431 instrument. The crude product was purified by HPLC.
p33 defines the major CTL epitope on LCMV-GP in the H-2
 
b
 
haplotype (33). To prevent disulphide bonds, the COOH-termi-
nal cysteine (C) has been replaced by methionine (M) (34).
 
In Vitro T Cell Proliferation, Production of IFN-
 
g
 
,
 
 
 
Induction of Ca
 
2
 
1
 
Flux, and Conjugate Formation.
 
Spleen cells from TCR-trans-
genic control or CD2-deficient mice (10
 
5
 
 cells/well) were stimu-
lated with thioglycollate-elicited macrophages (5 
 
3
 
 10
 
4
 
 cells/well)
derived from control or ICAM-1–deficient mice pulsed with
graded doses of peptide p33 or A4Y in flat-bottom 96-well plates.
Macrophages were pulsed for 1 h at 37
 
8
 
C and subsequently
washed two times. Proliferation was assessed 36 h later by pulsing
cultures with [
 
3
 
H]thymidine for 12 h. Production of IFN-
 
g
 
 was
assessed in supernatants as described (35). Induction of Ca
 
2
 
1
 
 flux
and presence of T cells forming specific conjugates was assessed as
described using INDO-1–pulsed T cells (Cat. no. I-3261; Sigma
Chemical Co.) (2).
 
Induction of TCR Downregulation.
 
Spleen cells from TCR-
transgenic mice (10
 
5
 
/well) were mixed with peptide pulsed mac-
rophages (2 
 
3
 
 10
 
5
 
/well) from control or ICAM-1–deficient
mice, centrifuged, and incubated at 37
 
8
 
C (5% CO
 
2
 
) in IMDM
 
supplemented with 10% FCS in round-bottom 96-well plates.
After 4 h, cells were harvested and stained for CD8 (PE; Phar-
Mingen) and V
 
a
 
2 (FITC; PharMingen); V
 
a
 
2 expression is shown
for CD8
 
1
 
 T cells (see Fig. 3).
 
In Vivo Activation of T Cells Using Peptide.
 
TCR-transgenic con-
trol or CD2-deficient mice were injected intravenously with var-
ious doses of peptide p33 in saline. 24 h later, spleen cells were
harvested and stained for expression of CD8 (FITC; PharMin-
gen), V
 
a
 
2 (PE; PharMingen), and CD44 (biotin; PharMingen)
followed by streptavidin–allophycocyanin (PharMingen) and ana-
lyzed by flow cytometry.
 
In Vivo Expansion and Effector Cell Induction.
 
Spleen cells from
TCR-transgenic CD2-deficient (CD45.2) or control (CD45.1)
mice (10
 
6
 
 cells) were adoptively transferred into normal C57BL/6
recipient mice. 1 h later, mice were challenged with live LCMV,
Vacc-GP, UV light–inactivated Vacc-LCMV-GP, or recombi-
nant LCMV-GP. 6 or 8 d later, spleen cells were harvested and
stained with anti-CD2 antibodies (FITC), anti-CD8 (allophyco-
cyanin), and anti-V
 
a
 
2 (PE) or with anti-CD45.1 (FITC), anti-
CD8 (allophycocyanin), and anti-V
 
a
 
2 (PE).
 
Results
 
Shifted Dose Response in the Absence of CD2–CD48 and
LFA-1–ICAM-1 Interaction.
 
We crossed CD2-deficient
mice with transgenic mice expressing a TCR specific for
LCMV-derived peptide p33 to study activation of CD2-
deficient T cells. To this end, splenocytes of CD2-deficient
and control TCR-transgenic mice were stimulated with
thioglycollate-elicited macrophages pulsed with various
concentrations of peptide p33. As shown in Fig. 1, the ab-
sence of CD2 shifted the dose–response curve by a factor of
3–10. To additionally analyze the role of the LFA-1–ICAM-1
interaction in this context, we compared ICAM-1–deficient
and control macrophages as APCs for CD2-deficient and
CD2-competent transgenic T cells. As reported previously
(2), the absence of LFA-1–ICAM-1 interaction shifted the
dose–response curve of T cells upon stimulation with graded
doses of peptide by a factor 10. Interestingly, the interference
with both CD2 and LFA-1 pathways shifted the dose re-
sponse by a factor of 
 
z
 
100. Thus, CD2 and LFA-1 facili-
tated T cell activation in an additive manner (Fig. 1).
As expected, if the low-affinity ligand A4Y was used for
the experiments, a similar albeit more pronounced shift in
the dose–response curve could be observed (Fig. 1). Mea-
surement of IFN-
 
g
 
 production showed results similar to
the proliferative response. Both CD2 and LFA-1 enhanced
IFN-
 
g
 
 production at low peptide concentrations, with the
effects being more dramatic upon stimulation with the
low-affinity ligand A4Y (Fig. 2). Thus, CD2–CD48 and
LFA-1–ICAM-1 regulate T cell responses similarly by re-
ducing the minimal amount of antigen required for activa-
tion and act in an additive manner.
 
CD2 Facilitates Generation of Signal 1 by Enhancing TCR
Triggering at Low Antigen Doses.
 
Functionally triggered TCRs
are internalized shortly after stimulation (4, 36). TCR down-
regulation can therefore be used to assess the number of
functionally triggered TCRs and thus the amount of signal 1
(3, 37). To assess whether CD2 altered the intensity of sig-
 
1
 
Abbreviation used in this paper:
 
 ICAM, intercellular adhesion molecule. 
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nal 1, T cells from TCR-transgenic control or CD2-defi-
cient mice were incubated with peptide-pulsed control or
ICAM-1–deficient macrophages. Expression levels of TCRs
were assessed 4 h later (Fig. 3, A and B). TCR downregu-
lation was reduced in the absence of either CD2 or ICAM-1
at low peptide densities (Fig. 3, A and B). Moreover, as ob-
served for the proliferative responses, ICAM-1 and CD2
acted in an additive fashion, and the dose–response curve of
 
TCR downregulation was similar to the dose–response curve
of the proliferative response (Fig. 3 B).
 
CD2 Promotes Ca
 
2
 
1
 
 Flux and Conjugate Formation at Low
Peptide Concentrations.
 
One of the earliest signals induced in
T cells upon antigenic stimulation are increased intracellular
free Ca
 
2
 
1
 
 levels ([Ca
 
2
 
1
 
]
 
i
 
). To test whether the enhanced
TCR triggering at low peptide concentrations in the pres-
ence of LFA-1–ICAM-1 or CD2–CD48 interactions would
Figure 1. CD2–CD48 and LFA-1–ICAM-1 interactions
enhance T cell proliferation at low peptide densities. Thio-
glycollate-elicited macrophages derived from control (filled
symbols) or ICAM-1–deficient (open symbols) mice were
pulsed with various doses of peptide p33 or the low-affin-
ity ligand A4Y and used to stimulate T cells derived from
TCR-transgenic control (squares) or CD2-deficient (cir-
cles) mice. Proliferation was assessed 36 h later by means of
[3H]thymidine incorporation. Two independent experi-
ments are shown. j, CD21ICAM1; d, CD22ICAM1;
h, CD21ICAM2; s, CD22ICAM2.
Figure 2. CD2–CD48 and LFA-1–ICAM-1 interac-
tion enhances IFN-g production at low peptide densities.
Thioglycollate-elicited macrophages derived from control
(filled symbols) or ICAM-1–deficient (open symbols) mice
were pulsed with various doses of peptide p33 or the low-
affinity ligand A4Y and used to stimulate T cells derived
from TCR-transgenic control (squares) or CD2-deficient
(circles) mice. Production of IFN-g was assessed by ELISA
3 d later from culture supernatants. Two independent rep-
resentative experiments are shown. j, CD21ICAM1; d,
CD22ICAM1; h, CD21ICAM2; s, CD22ICAM2. 
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translate into increased Ca
 
2
 
1
 
 fluxes, CD2-deficient and con-
trol T cells were loaded with INDO-1 and stimulated with
peptide-pulsed ICAM-1–deficient or control macrophages,
and [Ca
 
2
 
1
 
]
 
i
 
 was assessed (Fig. 4, A and B). As suggested by
the data on TCR downregulation, both CD2 on T cells and
ICAM-1 on APCs promoted increased [Ca
 
2
 
1
 
]
 
i
 
 at low antigen
concentrations (Fig. 4, A and B). Moreover, CD2–CD48 and
LFA-1–ICAM-1 interactions had an additive effect. Impor-
tantly, as previously observed for T cell clones (14), CD2 fa-
cilitated T cell–APC conjugate formation at low antigen con-
centrations, indicating that CD2 primarily promotes adhesion
of T cells to APCs (Fig. 5). Thus, the primary function of
CD2 seems to be to enhance adhesion of T cells to APCs at
low antigen concentrations, facilitating the generation of a T
cell–APC contact site required for sustained signaling (38).
 
CD2 Sets Quantitative Thresholds in T Cell Activation In
Vivo.
 
To assess the role of CD2 in T cell activation in vivo,
TCR-transgenic CD2-deficient and control mice were in-
jected with various doses of peptide p33 in saline, and ex-
pression of the activation marker CD44 was assessed 1 (Fig. 6)
and 3 d (not shown) later. As expected from the in vitro
experiments, presence of CD2 decreased the minimal amount
of peptide required for the upregulation of CD44.
To assess the role of CD2 in viral infections, an adop-
tive transfer system was employed (2, 39). Spleen cells (10
 
6
 
)
from TCR-transgenic CD2-deficient and control mice were
Figure 3. CD2–CD48 and LFA-1–ICAM-1 enhance T cell activation by altering signal 1. Thioglycollate-elicited macrophages derived from control
or ICAM-1–deficient mice were pulsed with various doses of peptide p33, mixed with T cells derived from TCR-transgenic control or CD2-deficient
mice, and centrifuged together. Expression of TCR (Va2) was assessed 4 h later on CD81 T cells. (A) TCR expression is shown for various combina-
tions after stimulation with 10210 M p33-pulsed macrophages. (B) Mean fluorescence of TCR expression is shown as a function of the peptide concen-
tration for the various combinations. One representative experiment of three is shown. j, CD21ICAM1; d, CD22ICAM1; h, CD21ICAM2; s,
CD22ICAM2.
Figure 4. CD2–CD48 and LFA-1–ICAM-1 enhance Ca21 fluxes at low antigen concentration. Thioglycollate-elicited macrophages derived from
control or ICAM-1–deficient mice were pulsed with various doses of peptide p33, mixed with INDO-1–pulsed, purified CD81 T cells derived from
TCR-transgenic control or CD2-deficient mice, and centrifuged together. Elevation of [Ca21]i was assessed by measuring the FL5/FL4 ratio. (A) FL5/FL4
ratio is shown after stimulation with 10211 M p33-pulsed macrophages. (B) Mean FL5/FL4 ratios are shown as a function of the peptide concentration for
the various combinations. Baseline FL5/FL4 values were subtracted for the calculation. One representative experiment of two is shown. j, CD21
ICAM1; d, CD22ICAM1; h, CD21ICAM2; s, CD22ICAM2. 
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mixed at a 1:1 ratio and adoptively transferred into nonirra-
diated C57BL/6 mice and immunized with LCMV (200
PFU) or a recombinant vaccinia virus expressing LCMV-
GP (Vacc-GP; 2 3 106 PFU). To enable selective identifi-
cation of the control versus CD2-deficient TCR-trans-
genic T cells, TCR-transgenic control mice on a CD45.1
background were used. Expansion of transferred TCR-
transgenic control and CD2-deficient T cells was subsequently
assessed 6 (Fig. 7) or 8 d (not shown) later. No significant
difference between CD2-deficient and control T cells was
observed. These results are in agreement with an earlier re-
port, in which CD2-deficient mice were found to mount
normal LCMV-specific CD81 T cell responses (27). Sur-
prisingly, even the absence of both functional CD2 and
LFA-1 together also failed to interfere with the response, as
CD2-deficient T cells transferred into ICAM-1–deficient
mice expanded normally upon infection with LCMV or
Vacc-GP (not shown).
The experiments performed so far suggested that CD2
plays a major role in T cell activation at low antigen densi-
ties. However, viral antigens are usually expressed at high
densities, and it may therefore not be surprising that CD2-
deficient T cells are able to respond normally to viral infec-
tions. To assess the role of CD2 in a situation where antigen
is less abundant, we used a recombinant vaccinia virus ex-
pressing LCMV-GP (Vacc-GP), which was inactivated with
UV light before infection. This treatment prevents the virus
from undergoing full replication cycles, and endogenously
produced antigens will therefore only reach low densities.
For the experiment, a 1:1 mixture of CD2-deficient TCR-
transgenic T cells obtained from CD45.2 mice and control
CD2-competent transgenic T cells obtained from CD45.1
mice (in a total of 106 spleen cells) was transferred into
C57BL/6 mice, which were subsequently immunized with
UV light–inactivated Vacc-GP (2 3 106 PFU before inacti-
vation). Control and CD2-deficient T cells could be conve-
niently distinguished by assessing CD45.1 versus CD45.2
and CD2 expression. As expected, the expansion of the
transferred T cells was dramatically reduced compared with a
challenge infection with live virus (Fig. 8 A). Moreover,
CD2-deficient T cells were clearly less efficiently proliferat-
ing than the control T cells. Note that CD45.11 and CD2-
deficient Va21CD81 T cells only account for z60% of the
cells. This is due to the presence of endogenous CD81Va21
T cells. Thus, CD2 expression on T cells becomes critical in
vivo in a situation where virus derived antigens are limiting.
CTLs are usually primed by endogenously produced an-
tigens reaching the class I pathway. However, MHC class I
molecules may under some conditions also be loaded by
exogenous antigens, leading to activation of specific T cells
in a process called cross-priming. We have previously shown
that exogenous LCMV-GP is able to reach the class I path-
way if associated with cellular debris (40). To test whether
CD2 may be required for optimal CTL induction upon
cross-priming, a 1:1 mixture of CD2-deficient (CD45.2)
and control (CD45.1) TCR-transgenic T cells (total of 106
spleen cells) was transferred into C57BL/6 mice, which were
subsequently immunized with recombinant LCMV-GP in
association with cellular debris. 6 d later, the presence of
CD45.11 control and CD2-deficient TCR-transgenic T cells
was assessed in the spleen (Fig. 8 B). Although the CD2-
deficient T cells were activated and proliferated upon cross-
priming, the expansion was less dramatic than that observed
for the control cells. This indicates that CD2 participates in
regulation of T cell expansion upon cross-priming.
Discussion
This study demonstrates that CD2–CD48 and LFA-1–
ICAM-1 interactions enhance T cell activation in an addi-
Figure 5. CD2–CD48 interaction enhances T cell–APC conjugate for-
mation. Thioglycollate-elicited macrophages were pulsed with various
doses of peptide p33, mixed with INDO-1–pulsed, purified CD81 T cells
derived from TCR-transgenic control (j) or CD2-deficient (d) mice, and
centrifuged together, and conjugate formation was assessed. Data from two
independent experiments were pooled, and the average and SD is shown.
Figure 6. CD2 reduces the amount of peptide required for in vivo in-
duction of CD44 expression. TCR-transgenic control (j) and CD2-
deficient (d) mice were injected with various amounts of peptide p33,
and expression of CD44 was assessed 24 h later on CD81Va21 T cells.
The average of two mice is shown per dose. One representative experi-
ment of three is shown.1388 CD2 Sets Quantitative Thresholds in T Cell Activation
tive fashion by similar mechanisms. Both interactions facili-
tate TCR triggering by increasing T cell–APC interactions
at low antigen densities, fine-tuning T cell responses in vitro
and in vivo.
CD2 as an Accessory Molecule: Adhesion Versus Costimulation.
T cell activation may be described in terms of the two-sig-
nal model, where signal 1 describes TCR-mediated signals
and signal 2 refers to signals delivered by costimulatory
molecules, which facilitate full T cell activation and pre-
vent the induction of T cell tolerance (2, 41–43); we have
operationally discriminated these as signal 2c and 2t, re-
spectively (2). As TCRs productively triggered by MHC–
peptide complexes are rapidly internalized (4, 36), the rate
of TCR internalization may serve as a quantitative measure
for the amount of signal 1 a T cell is receiving at a given
time point (2). Thus, a true costimulatory molecule would
enhance T cell activation without changing signal 1, i.e.,
TCR internalization (unless it modulates the ratio of TCR
engagement versus internalization) (2). This is the case for
CD28, which does not affect TCR internalization but nev-
ertheless enhances T cell activation, apparently by increas-
ing TCR-mediated signals intracellularly (2, 3, 30). It has
recently been suggested that rearrangement of membrane
rafts rich in glycosphingolipids may be critical in this pro-
cess (44, 45). In contrast, CD2 does not seem to affect T
cell activation other than by increasing signal 1 (i.e., the
number of triggered TCRs) at low antigen densities. In
fact, the dose–response curves of T cell–APC conjugation,
TCR internalization, Ca21 flux, and T cell proliferation are
similarly shifted toward higher antigen concentrations in
the absence of CD2, indicating that CD2 enhances T acti-
vation by facilitating T cell–APC interactions at low anti-
gen densities. Thus, CD2 may be viewed as an adhesion
molecule rather than a costimulatory molecule. This view
is compatible with the recent observation that CD2 recruits
an adapter molecule (CD2AP) to the T cell–APC contact
site, helping to rearrange the cytoskeleton. Such a rear-
rangement is presumably required for a firm and stable T
cell–APC interaction (28). Our observations also fit the hy-
pothesis that CD2 may bring T cells and APCs into close
proximity, helping to exclude large molecules such as
CD45 from the contact site (16). In particular, the finding
Figure 7. Normal in vivo expansion of LCMV-GP–
specific, CD2-deficient, TCR-transgenic T cells upon
infection with live virus. CD45.11 TCR-transgenic
control spleen cells were mixed 1:1 with CD45.11
CD2-deficient spleen cells and adoptively transferred
into C57BL/6 recipient mice. (A) Left panel: 1:1 dis-
tribution of CD21 and CD22 TCR1 T cells was con-
firmed before transfer. Center and right panels: spleno-
cytes from mice that received 106 cells of the mixture
shown in the left panel 6 d earlier in the absence of an
infection were stained for Va2, CD8, and CD45.1 ex-
pression;  ,2% of CD81Va21 T cells were derived
from the adoptively transferred T cells. (B and C) Re-
cipient mice were infected with LCMV (200 PFU; B)
or recombinant vaccinia virus expressing LCMV-GP
(2 3 106 PFU; C). CD45.1 expression was assessed for
CD81Va21 T cells, revealing expansion of CD21 con-
trol T cells (upper right panels). CD2 expression was
assessed similarly for CD81Va21 T cells, revealing ex-
pansion of CD2-deficient T cells (lower right panels).
Similar results were obtained 8 d after infection. One
representative experiment of three is shown.1389 Bachmann et al.
that CD2 is dispensable at high antigen concentrations may
be explained by the notion that (a) the sizes of the TCR
and CD2 are similar and (b) the CD2–CD48 interaction
exhibits an affinity that is on the order of the TCR MHC–
peptide interaction. Thus, large numbers of TCR MHC–
peptide interactions may be able to substitute for CD2.
We have previously argued that LFA-1 effects activation
of CD81 T cells primarily by promoting T cell–APC adhe-
sion (2). This may be different for CD41 T cells, as it has
been reported that LFA-1 specifically promotes Th1 devel-
opment (46). Thus, it remains possible that CD2 may affect
activation of CD41 T cells in a similarly qualitative fashion.
However, we recently found that LFA-1 shifts the Th1/
Th2 cytokine balance by shifting the dose response of
CD41 Th cells. In fact, absence of LFA-1 increased the
minimal antigen concentration required for activation of
TCR-transgenic Th cells by a factor of z100 (Ruedl, C.,
M.F. Bachmann, and M. Kopf, manuscript submitted for
publication). Because induction of Th1 cells was also
shifted by a factor of 100, this indicated that absence of
LFA-1 shifted the response from Th1 to Th2 by globally
shifting the dose response of CD41 Th cells. Thus, al-
though we cannot exclude the possibility that CD2 affects
CD41 T cell responses distinctly from CD81 T cell responses,
there is no data supporting such an assumption at this point.
The In Vivo Role of CD2.  CD2-deficient mice have been
found to mount largely normal T cell responses upon in-
fection with LCMV (27). In the light of our observation
that CD2 is dispensable for T cell activation at high antigen
concentrations, this earlier finding may not be surprising, as
viral infection usually leads to high local antigen density.
Using CD2-deficient T cells from TCR-transgenic mice
specific for a peptide derived from LCMV, we could con-
firm the CD2 independence of the anti-LCMV CTL re-
sponse (27). Moreover, using a recombinant vaccinia virus
expressing LCMV-GP, we could demonstrate that the
CTL response elicited by vaccinia virus was also CD2 inde-
pendent. More surprisingly, T cell responses were still un-
affected in the absence of both LFA-1–ICAM-1 and CD2–
CD48 interactions (not shown). Thus, antiviral immune
responses may often be generated in the absence of CD2
and/or LFA-1. However, CD81 T cell activation was clearly
impaired in vivo in the absence of CD2 if limited amounts
of antigen were used for immunization, as, for example,
with immunization regimens involving low amounts of
peptide or UV light–inactivated recombinant vaccinia vi-
rus. The latter results may be particularly interesting be-
cause they indicate that viruses do not target a particular
APC in vivo that can prime CTLs in the absence of CD2
but rather suggest that CD2 dependence is dictated by anti-
gen quantity. Thus, viruses that replicate intracellularly to
high titers can prime T cells in the absence of CD2,
whereas abortive viral infections that do not reach high lev-
els of intracellular protein require CD2 for full T cell acti-
Figure 8. Impaired in vivo expansion of LCMV-GP–
specific, TCR-transgenic, CD2-deficient T cells upon
cross-priming. CD45.11 TCR-transgenic control spleen
cells were mixed 1:1 with CD45.11 CD2-deficient spleen
cells and adoptively transferred into C57BL/6 recipient
mice. (A) Recipient mice were immunized with UV
light–inactivated recombinant vaccinia virus expressing
LCMV-GP, and spleen cells were analyzed 6 d later.
CD45.1 expression was assessed for CD81Va21 T cells,
revealing expansion of CD21 control T cells (upper right
panels). CD2 expression was assessed similarly for CD81
Va21 T cells, revealing expansion of CD2-deficient T
cells (lower right panels). (B) Recipient mice were immu-
nized with LCMV-GP associated with cellular debris, and
spleen cells were analyzed 6 d later. CD45.1 expression
was assessed for CD81Va21 T cells, revealing expansion of
CD21 control T cells (upper right panels). CD2 expression
was assessed similarly for CD81Va21 T cells, revealing ex-
pansion of CD2-deficient T cells (lower right panels). Per-
centage of CD45.11 control T cells versus CD2-deficient
T cells was ,3% in the absence of immunization. One
representative experiment of two is shown.1390 CD2 Sets Quantitative Thresholds in T Cell Activation
vation. This latter class of immunization may therefore be
representative for infections with attenuated viruses that in-
duce only abortive infections. Moreover, antigens intro-
duced to the immune system by cross-presentation also
did not reach high densities of class I molecules and there-
fore required the presence of CD2 for optimal T cell re-
sponses. Thus, T cell responses against abundant antigens
occur in the absence of CD2, whereas T cell responses
against rare and cross-presented antigens require the pres-
ence of CD2 for optimal responses.
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